Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis

Hepatology

Volumn 37, Issue 3, 2003, Pages 544-550

  Chalasani, Naga ^a   Christopher Gorski, J ^a   Asghar, Maleeha S ^a   Asghar, Ali ^a   Foresman, Brian ^a   Hall, Stephen D ^a   Crabb, David W ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYBUTYRIC ACID; CHLORZOXAZONE; CYTOCHROME P450 2E1; GLUCOSE; INSULIN; LIPID; MESSENGER RNA;

ADULT; AGE; ANTHROPOMETRIC PARAMETERS; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMOGRAPHY; DIET RESTRICTION; ENZYME ACTIVITY; FATTY LIVER; FEMALE; GENDER; GLUCOSE BLOOD LEVEL; HUMAN; HYPOXEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID BLOOD LEVEL; LYMPHOCYTE; MALE; NONALCOHOLIC FATTY LIVER; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SLEEP DISORDER;

EID: 0037369729     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2003.50095     Document Type: Article

References (37)

1. Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis 2001;21:17-26.
2. Robertson G, Leclercq I, Farrell GC. II. Cytochrome P-450 enzymes and oxidative stress. Am J Physiol Gastrointest Liver Physiol 2001;281:G1135-G1139.
3. Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, Luketic VA, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001;120:1183-1192.
4. Chalasani N, Gupta MP, Crabb DW. In vivo assessment of lipid peroxidation in non-alcoholic steatohepatitis [Abstract]. HEPATOLOGY 2001; 34(Part 2):457A.
5. James O, Day C. Non-alcoholic steatohepatitis: another disease of affluence. Lancet 1999;353:1634-1636.
6. Weltman MD, Farrell GC, Liddle C. Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation. Gastroenterology 1996;111:1645-1653.
7. Leclercq IA, Farrell GC, Field J, Bell DR, Gonzalez FJ, Robertson GR. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Invest 2000;105:1067-1075.
8. Weltman MD, Farrell GC, Hall P, Ingelman-Sundberg M, Liddle C. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. HEPATOLOGY 1998;27:128-133.
9. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413-1419.
10. Dempster P, Aitkens S. A new air displacement method for the determination of human body composition. Med Sci Sports Exerc 1995;27:1692-1697.
11. Wagner DR, Heyward VH, Gibson AL. Validation of air displacement plethysmography for assessing body composition. Med Sci Sports Exerc 2000;32:1339-1344.
12. Miyatake N, Nonaka K, Fujii M. A new air displacement plethysmograph for the determination of Japanese body composition. Diabetes Obes Metab 1999;1:347-351.
13. Yoshizumi T, Nakamura T, Yamane M, Islam AH, Menju M, Yamasaki K, Arai T, et al. Abdominal fat: standardized technique for measurement at CT. Radiology 1999;211:283-286.
14. Mather KJ, Hunt AE, Steinberg HO, Paradisi G, Hook G, Katz A, Quon MJ, et al. Repeatability characteristics of simple indices of insulin resistance: implications for research applications. J Clin Endocrinol Metab 2001;86:5457-5464.
15. Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, Karim R, et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. HEPATOLOGY 2002;35:373-379.
16. Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, Forlani G, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999;107:450-455.
17. Peter R, Bocker R, Beaune PH, Iwasaki M, Guengerich FP, Yang CS. Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1. Chem Res Toxicol 1990;3:566-573.
18. Frye RF, Adedoyin A, Mauro K, Matzke GR, Branch RA. Use of chlorzoxazone as an in vivo probe of cytochrome P450 2E1: choice of dose and phenotypic trait measure. J Clin Pharmacol 1998;38:82-89.
19. Burckart GJ, Frye RF, Kelly P, Branch RA, Jain A, Fung JJ, Starzl TE, et al. Induction of CYP2E1 activity in liver transplant patients as measured by chlorzoxazone 6-hydroxylation. Clin Pharmacol Ther 1998;63:296-302.
20. Lucas D, Menez JF, Berthou F. Chlorzoxazone: an in vitro and in vivo substrate probe for liver CYP2E1. Methods Enzymol 1996;272:115-123.
21. Girre C, Lucas D, Hispard E, Menez C, Dally S, Menez JF. Assessment of cytochrome P4502E1 induction in alcoholic patients by chlorzoxazone pharmacokinetics. Biochem Pharmacol 1994;47:1503-1508.
22. Gorski JC, Jones DR, Wrighton SA, Hall SD. Contribution of human CYP3A subfamily members to the 6-hydroxylation of chlorzoxazone. Xenobiotica 1997;27:243-256.
23. Asghar A, Gorski JC, Haehner-Daniels B, Hall SD. Induction of multidrug resistance-1 and cytochrome P450 mRNAs in human mononuclear cells by rifampin. Drug Metab Dispos 2002;30:20-26.
24. Weaver TE, Laizner AM, Evans LK, Maislin G, Chugh DK, Lyon K, Smith PL, et al. An instrument to measure functional status outcomes for disorders of excessive sleepiness. Sleep 1997;20:835-843.
25. Little SA, Elkholy MM, Chalmers GW, Farouk A, Patel KR, Thomson NC. Predictors of nocturnal oxygen desaturation in patients with COPD. Respir Med 1999;93:202-207.
26. Ekstrom G, Ingelman-Sundberg M. Rat liver microsomal NADPH-supported oxidase activity and lipid peroxidation dependent on ethanol-inducible cytochrome P-450 (P-450IIE1). Biochem Pharmacol 1989;38: 1313-1319.
27. Kurdi J, Maurice H, El Kadi AO, Ong H, Dalkara S, Belanger PM, Souich P. Effect of hypoxia alone or combined with inflammation and 3-methylcholanthrene on hepatic cytochrome P450 in conscious rabbits. Br J Pharmacol 1999;128:365-373.
28. Barcelo A, Miralles C, Barbe F, Vila M, Pons S, Agusti AG. Abnormal lipid peroxidation in patients with sleep apnoea. Eur Respir J 2000;16:644-647.
29. Bayanov AA, Brunt AR. Role of hypoxia and constitutionally different resistance to hypoxia/stress as the determiners of individual profile of cytochrome P450 isozyme activity. Gen Pharmacol 1999;33:355-361.
30. Raucy J, Carpenter SP. CYP2E1. In: Levy RH, Thummel KE, Trager WF, Hansten PD, Eichelbaum M, eds. Metabolic Drug Interactions. Philadelphia: Lippincott, Williams & Wilkins, 2000;95-113.
31. Tierney DJ, Haas AL, Koop DR. Degradation of cytochrome P450 2E1: selective loss after labilization of the enzyme. Arch Biochem Biophys 1992; 293:9-16.
32. Roberts BJ, Song BJ, Soh Y, Park SS, Shoaf SE. Ethanol induces CYP2E1 by protein stabilization. Role of ubiquitin conjugation in the rapid degradation of CYP2E1. J Biol Chem 1995;270:29632-29635.
33. Woodcroft KJ, Novak RF. Insulin effects on CYP2E1, 2B, 3A, and 4A expression in primary cultured rat hepatocytes. Chem Biol Interact 1997;107:75-91.
34. De Waziers I, Garlatti M, Bouguet J, Beaune PH, Barouki R. Insulin down-regulates cytochrome P450 2B and 2E expression at the post-transcriptional level in the rat hepatoma cell line. Mol Pharmacol 1995;47:474-479.
35. Woodcroft KJ, Hafner MS, Novak RF. Insulin signaling in the transcriptional and posttranscriptional regulation of CYP2E1 expression. HEPATOLOGY 2002;35:263-273.
36. Raucy JL, Schultz ED, Wester MR, Arora S, Johnston DE, Omdahl JL, Carpenter SP. Human lymphocyte cytochrome P450 2E1, a putative marker for alcohol-mediated changes in hepatic chlorzoxazone activity. Drug Metab Dispos 1997;25:1429-1435.
37. Charlton M, Sreekumar R, Rasmussen D, Lindor K, Nair KS. Apolipoprotein synthesis in nonalcoholic steatohepatitis. HEPATOLOGY 2002;35:898-904.